$NWBO: ATL-DC IS DCVax-L - Part 2.
ATL-DC is DCVax-L.
Already in 2016, Robert Prins talked about the UCLA work with NWBO and the promise of combo trials with BMY and Merck, combining DCVax-L with PD-1 inhibitors, namely in this presentation entitled "The Future of Vaccine Treatment in Brain Cancer from the Seattle Science Foundation.
Work, we've come to know as the SPORE project 1.
2016
https://www.youtube.com/watch?v=GkvsB0rdm3Y&ab_channel=SeattleScienceFoundation
In this excerpt he stated the following, explicitly stating DCVax-L.
2017
This seems to be work done (2017) by many from the same UCLA group that led up to the 2023 study lead by Robert Prins, researching WHY checkpoint inhibitors are inefficient without DCVax-L. Prins, Liau and Cloughesy among others.
https://jstor.org/stable/26487966
Work leading us up to ....
2023
Where Robert Prins tells about the outcome in this article ....
https://www.uclahealth.org/news/why-certain-brain-tumors-dont-respond-to-immunotherapy
Referring to the research in this article ...
https://www.jci.org/articles/view/169314
And 10 days after, several of the same authors from the above team, gets this article in pre-print in Nature.
https://www.researchsquare.com/article/rs-3287211/v1
Northwest Biotherapeutics is even MENTIONED as a grant supportor for the work done leading up to this Nature article.
How obvious can it be?
You can look into these grants by yourself here (Linda Liau as example)
Linda Liau (R01-CA112358)
https://grantome.com/grant/NIH/R01-CA112358-05
But lets dwell with Robert Prins for a moment and search for "DCVax" among grants.
https://www.grantome.com/search?q=dcvax
That was kind of interesting. Project 1 is the UCLA Spore 1 trial which is the combo trial with DCvax-L and currently, Keytruda. Here you can see the development of this project.
Robert Prins was assigned to it in 2017-2019, and look ... Linda Liau takes over in 2020.
What did also change when she "took over"?
It was plain for EVERYONE to see, that DCVax-L was used in the SPORE-1 project under Robert Prins.
But hey ... DCVax-L is STILL mentioned here when Linda Liau takes over. Can you see, that DCvax-L was meant to be tested with Bristol Meyers Squibbs NIVOLUMAB (Opdivo) checkpoint inhibitor?!
Well, we can directly check the evolvement of the SPORE 1 project on the Way Back Machine
2020 (correlates completely)
In March 2022 we get a change
And in April 2022 another
And lastly the current one in november 2022 (the only one obfuscating the DCVax-L term with ATL-DC)
If one follow Robert Prins' work, we can see his work researching the efficacy of checkpoint inhibitors and DCvax starting here above in 2016, led him to another "pathway". They obviously felt, his research was better spent elsewhere and instead supporting Linda Liau "along the way" with his teams results, which could then again be incorporated dynamically as changes in the SPORE 1 projects and its aims, as they collectively become wiser.
Safe to say, that there's put an abundant of resources into this, not least through the grants payed by NIH.
But best of all. Look at the current aim 2.
PLX3397 and Pembrolizum (Keytruda). Daichii and Merck ... who signed a deal with each other few months ago. They have already done several clinical trials with these two drugs. That was terminated. Also in recurrent glioblastoma.
It seems as if they believe they are missing one vital key ingredient?
Can you guess which one?
If anyone believes Merck is not STILL very much "in this game", well ... I guess you also choose to remain clueless about the term ATL-DC.